IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Human Papilloma Virus
National Cancer Institute (NCI)protein_peptidePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 39/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Human Papilloma Virus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gardasil 9 Vaccine Eunice Dube | Phase 4 | BBB |
Recombinant Nonavalent Human Papillomavirus Vaccine Beijing Health Guard Biotechnology, Inc | Phase 3 | BB |
HUMAN PAPILLOMAVIRUS SEROTYPE 58 WHOLE Beijing Health Guard Biotechnology, Inc | Phase 3 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
FLUOROURACILUM AIDS Malignancy Consortium | Phase 3 | BB |
View all 16 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →